MHRA Recalls Novartis Cough and Cold Medicine

Article

Agency issues precautionary recall due to manufacturing fault.

The Medicines and Healthcare products Regulatory Agency (MHRA) issued a recall on certain batches of Novartis Consumer Health UK Ltd’s Tixylix cough and cold medicines because of a possible fault in the manufacturing process of the tamper seal that might result in small pieces of plastic being found in the liquid medicines. MHRA says that there is no evidence, as of yet, of problems occurring as a result of this manufacturing fault but they are recalling the drugs as a precautionary measure.

“This is a precautionary recall and there is currently no evidence that people have had any problems with these medicines,” said Adam Burgess, the MHRA’s Head of Defective Medicines Reporting Centre (DMRC), in a press release.“If people have bought Tixylix we ask that they check the batch number on the bottle label next to the expiry date to see if it is one of the batches being recalled. If anyone has an affected batch they should return it to the place of purchase for a refund. If people do have any questions they can contact Novartis on 0800 854 100 or visit tixylix.co.uk.”

Specific batches of the Tixylix medicines being recalled by Novartis include:
Tixylix Toddler Syrup 100mL (Glycerol)—PL 00030/0150
Tixylix Toddler Syrup 150mL (Glycerol)—PL 00030/0150
Tixylix Baby Syrup 100mL (Glycerol)—PL 00030/0150
Tixylix Blackcurrant Flavour Syrup 100mL (Glycerol)—PL 00030/0150
Tixylix Chesty Cough 100mL (Guaifenesin)—PL 00030/0082

Source: MHRA

Recent Videos
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services